ASCO 2009: Adding Gemcitabine to Standard Therapy Improves Survival in Cervical Cancer Patients

Roxanne Nelson


June 2, 2009 (Orlando, Florida) —The addition of gemcitabine (Gemzar) to cisplatin-based chemotherapy and radiation appears to improve overall and progression-free survival in women with locally advanced cervical cancer.

"To our knowledge, the data from this trial represent the first finding of significantly improved survival outcomes for locally advanced cervical cancer treated with combination chemotherapy and concurrent radiation, over single-agent cisplatin with concurrent radiation," said lead author Alfonso Dueñas-González, MD, PhD, a cancer researcher at the National Cancer Institute of Mexico and the Instituto of Biomedical Research UNAM in Mexico City.

Dr. Dueñas-González presented his research at an oral session here at the American Society of Clinical Oncology 45th Annual Meeting.

At a median follow-up of 3 years, progression-free survival was 74% in patients who received gemcitabine, compared with 65% in those who received standard therapy, and this improvement reached statistical significance, explained Dr. Dueñas-González.

^ oldal tetejére